Fertility Preservation with GnRH Analogues during Chemotherapy
Introduction to GnRH Analogues
- The American Society of Clinical Oncology (ASCO) states that GnRH analogues are not an effective method for fertility preservation 1, 2
- The use of GnRH agonists or antagonists during chemotherapy is a highly controversial method for preserving fertility, with some studies showing benefit in maintaining menstrual function, while others show no advantage 3, 4, 5, 1
Guideline Recommendations
- The NCCN AYA Oncology (2017) guidelines indicate that there is insufficient evidence to support the use of GnRH analogues for protecting ovarian function, and they are not recommended as an option for fertility preservation 6, 7
- The ESMO (2013) guidelines state that GnRH analogues should not be considered a reliable means of fertility preservation 6, 7
- The ASCO guidelines recommend that GnRH analogues should not be used as the sole method for fertility preservation in patients receiving chemotherapy with Epirubicin and Ifosfamid 1, 2
Considerations for Clinical Practice
- Established methods of fertility preservation, such as embryo or egg cryopreservation, should be preferred over GnRH analogues 6, 8
- GnRH analogues may be considered as an unproven option in emergency situations or when established options are not available, preferably within a clinical trial setting 1, 2
- Patients should be informed about the controversial data and encouraged to participate in clinical trials 3, 9
Limitations and Concerns
- Complete ovarian suppression is only achieved several weeks after starting treatment with GnRH analogues 1, 2
- Side effects, such as hot flashes and bone loss, can occur with the use of GnRH analogues 1, 2
- Most studies use resumption of menstruation as an endpoint, rather than actual fertility 3, 9
- There are concerns about potential risks in patients with hormone-sensitive tumors 3, 5
GnRH Agonists and Antagonists in Clinical Practice
Introduction to GnRH Analogues
- The American Society of Clinical Oncology and other guideline societies use "GnRH analogues/agonists" or "GnRH agonists or antagonists" interchangeably when discussing fertility preservation, as both classes theoretically could suppress gonadotropins, though the evidence for either remains controversial 10, 11, 12
Clinical Implications and Usage
- In clinical practice, "GnRH analogs" is used as shorthand when the distinction doesn't matter clinically, according to the European Society of Human Reproduction and Embryology 10
- "GnRH agonists" are specified when discussing the flare phenomenon or specific agents, as recommended by the American Society of Clinical Oncology 11
- "GnRH agonists or antagonists" are considered for the same indication, as suggested by the National Comprehensive Cancer Network 11, 12